TGFB1 and neoplasm: TGF-β released from cancer cells, stromal fibroblasts and other cells can shape the architecture of the TME by suppressing the antitumor activities of immune cells to attenuate the anti-tumor efficacy of ICIs (Mariathasan et al., 2018; Derynck et al., 2020).